Moving discovery to development, the Genopole ecosystem ensures fluidity between research, clinical trials, valorization and industrial development. To carry out its mission, Genopole pilots a program of actions and services comprising strong support to academic research teams, constant enrichment of the shareduse technological platforms, a Booster program to consolidate the growth of start-ups, a team of project managers to provide entrepreneurial guidance, the organization of events to share information and exchange ideas, and much more. In a tumultuous year, Genopole adapted its accompaniment strategy and reaffirmed its role as a catalyzer. New companies set up shop at the biocluster, which was able to count on the Île-de-France Administrative Region to favor its industrialization.


26 technological platforms to support research and innovation

The biocluster’s shared-use, state of the art technological equipment and the competencies that go with them—called “platforms” in Genopole parlance—are a major development lever for its laboratories and businesses. Every year, the platform offer grows to respond to the changing needs of the labs and businesses and the emergence of novel scientific and industrial orientations.

A new platform

In 2020, Genopole strengthened its shared-use sequencing offer by accrediting the NGS & genomics analyses platform at I-Stem and participating in the financing of a range of equipment, notably an Illumina NextSeq 550 sequencer. The enablement of academic partnerships and the four-fold increase in sequencing capacities will contribute greatly to the expansion of genomics and biotherapies at Genopole.

Dedicated services for innovative therapies

The Cytopolis building now has its own scientific ancillary services suite. It is available to the building’s two specialists in biotherapies R&D and industrial development: ART-TG (gene therapies) and CiTHERA (cell therapies).

Supplying concrete technological solutions

  • The bioproduction platform has added four mini-fermenters for bacteria and yeast cultures. That addition upscales production processes, which now range from small 350 mL volumes to large 20-liter pilot-level volumes. The platform is thus further empowering the bioeconomy sector at Genopole.
  • Also in the year and with Genopole’s aid, the mass spectrometry platform acquired four major pieces of equipment to guarantee high-quality analyses of, for example, bioproduced finished projects.
  • In 2020, Genopole’s technological support project Saturne attributed six pieces of equipment. These included such items as an RNA extractor, a flow cytometer, an epifluorescence video microscope, and particularly an Opera Phenix+ for the structural biology platform. Cofinanced by the University of Évry, that system is able to generate tens of thousands of high-resolution images in a matter of hours. The platform thus becomes Europe’s first to have this novel system.

A dynamic partnership network in 2020 despite the crisis